Systemic Sclerosis and Serum Content of Transforming Growth Factor

Majewski, Dominik; Majewska, Katarzyna Anna; Kuźnar-Kamińska, Barbara; Runowska, Marta; Piorunek, Tomasz; Batura‐Gabryel, Halina; Puszczewicz, Mariusz

doi:10.1007/5584_2019_341

Cited by 4 publications

(2 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This result is in accordance with one study reported in the United Kingdom for sTGF-β1 [20], but in contrast to one reported in Brazil, where sTGF-β1 was higher in SSc patients than in CS [21]. Other studies have reported no signi cant differences [22][23][24].…”

Section: Discussionsupporting

confidence: 92%

“…The discrepancies observed in SSc patients regarding TGF-β isoform levels must be clari ed with further studies; however, some authors suggest that those could be due to methodological differences in the quanti cation of TGF-β isoforms because not all of them discriminate between the latent and active forms [20,22]. Dziadzio et al evaluated both forms (latent and active) and only found differences for the active TGF-β1 form, which was lower in dcSSc patients than in CS [20].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Transforming Growth Factor Beta Isoforms and TGF-βR1 and TGF-βR2 Expression in Systemic Sclerosis Patients

Lomelí-Nieto

Muñoz‐Valle

Baños‐Hernández

et al. 2022

Preprint

View full text Add to dashboard Cite

Systemic sclerosis (SSc) is characterized by chronic inflammation and fibrosis, two processes associated with transforming growth factor β (TGF-β) functions. In the present study, we investigated the expression of TGF-β isoforms in serum and the skin distribution of TGF-β and two receptors (TGF-βR1 and TGF-βR2) in SSc patients. A total of 56 SSc patients and 120 control subjects (CS) were included. The serum levels of TGF-β isoforms were quantified by immunoassay with magnetic microspheres, and the skin biopsies were processed by immunohistochemistry (IHC). The soluble levels of the three active TGF-β isoforms were lower in SSc patients than in CS (p < 0.0001). However, sTGF-β1 and sTGF-β3 levels were positively correlated with C-reactive protein (CRP) levels in SSc patients. Additionally, sTGF-β2 and sTGF-β3 levels were positively correlated with the number of platelets in SSc patients. In skin biopsies, TGF-β1, TGF-βR1, and TGF-βR2 expression levels were higher in SSc patients than CS. In conclusion, this is the first study showing a joint decrease of the 3 active TGF-β isoforms in SSc patients. However, TGF-β1, TGF-βR1, and TGF-βR2 are possibly increased in clinically involved skin. Therefore, it is likely that a distinct role is played by TGF-β at the local (skin lesions) and systemic levels in SSc patients.

show abstract